S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCI... за авторством E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, D. Fotiou, N. Kanellias, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.-A. Dimopoulos

Отримати повний текст

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK за авторством E. Kastritis, M. C. Minnema, M. A. Dimopoulos, G. Merlini, F. Theodorakakou, D. Fotiou, A. Huart, K. Belhadj, S. Gkolfinopoulos, K. Manousou, P. Sonneveld, G. Palladini

Отримати повний текст

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK за авторством E. Kastritis, G. Palladini, M. A. Dimopoulos, A. Jaccard, G. Merlini, F. Theodorakakou, D. Fotiou, M. C. Minnema, A. Wechalekar, S. Gkolfinopoulos, K. Manousou, P. Sonneveld, S. Schönland

Отримати повний текст

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY за авторством V. Spiliopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, M. Gavriatopoulou, F. Theodorakakou, D. Fotiou, R. E. Syrigou, M. Migkou, M. Roussou, E. Eleutherakis-Papaiakovou, E. Kastritis, M. A Dimopoulos, E. Terpos

Отримати повний текст

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA за авторством I. Ntanasis-Stathopoulos, M. Gavriatopoulou, E. Eleutherakis-Papaiakovou, P. Malandrakis, V. Spiliopoulou, R.E. Syrigou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Roussou, E. Kastritis, M.A. Dimopoulos, E. Terpos

Отримати повний текст

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL за авторством I. Ntanasis-Stathopoulos, M. Gavriatopoulou, P. Malandrakis, D. Fotiou, N. Kanellias, M. Migkou, F. Theodorakakou, V. Spiliopoulou, R. Syrigou, E. Eleutherakis-Papaiakovou, S. Gkolfinopoulos, K. Manousou, E. Kastritis, M.A. Dimopoulos, E. Terpos

Отримати повний текст

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA за авторством P. Malandrakis, I. Ntanasis-Stathopoulos, I.V. Kostopoulos, P. Roussakis, E. Eleutherakis-Papaiakovou, C. Panteli, N. Angelis, V. Spiliopoulou, N. Orologas-Stavrou, F. Theodorakakou, D. Fotiou, M. Migkou, M. Gavriatopoulou, E. Kastritis, O.E. Tsitsilonis, M.A. Dimopoulos, E. Terpos

Отримати повний текст